logo
Plus   Neg
Share
Email

Pozen Inc. (POZN) Is Up Sharply On Study Results

Pozen Inc. (POZN) reported positive results from two Phase 3 clinical trials of PA32540, a coordinated-delivery tablet of immediate-release omeprazole and delayed release aspirin. The primary endpoint were met in both studies and the studies met their key secondary endpoints.

Pozen has gapped open sharply higher Thursday morning and is now up 0.80 at $5.60, with volume at nearly a 4-month high. The stock has surged to a 10-month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT